<DOC>
	<DOCNO>NCT00056589</DOCNO>
	<brief_summary>This trial conduct United States America ( USA ) . The aim trial investigate safety pharmacokinetics escalate single dos catridecacog ( recombinant factor XIII , rFXIII ) patient congenital factor XIII deficiency .</brief_summary>
	<brief_title>Safety Pharmacokinetics Recombinant Factor XIII Patients With Congenital Factor Xlll Deficiency</brief_title>
	<detailed_description />
	<mesh_term>Blood Coagulation Disorders</mesh_term>
	<mesh_term>Hemostatic Disorders</mesh_term>
	<criteria>Documental congenital FXIII deficiency Normal platelet count clot parameter Adequate renal hepatic function If female childbearing potential , negative serum pregnancy test within 7 day enrollment If sexually active male sexually active female childbearing potential , agreement use medically accept form contraception time enrollment completion followup study visit Negative drug alcohol screen Received blood product FXIII concentrate within 4 week study enrollment Known antibody FXIII Hereditary acquire coagulation disorder FXIII deficiency Previous history autoimmune disorder involve autoantibody e.g. , systemic lupus erythematosus Previous history thromboembolic event e.g. , cerebrovascular accident deep vein thrombosis administration antithrombotic antiplatelet drug within 7 day study enrollment Received treatment experimental agent within 30 day study enrollment Any surgical procedure 30 day prior enrollment Donated blood within 30 day prior enrollment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>